Logo image of OTLK

OUTLOOK THERAPEUTICS INC (OTLK) Stock Fundamental Analysis

NASDAQ:OTLK - Nasdaq - US69012T3059 - Common Stock - Currency: USD

1.84  +0.04 (+2.22%)

After market: 1.76 -0.08 (-4.35%)

Fundamental Rating

1

OTLK gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. OTLK has a bad profitability rating. Also its financial health evaluation is rather negative. OTLK has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

OTLK had positive earnings in the past year.
OTLK had a negative operating cash flow in the past year.
In the past 5 years OTLK always reported negative net income.
In the past 5 years OTLK always reported negative operating cash flow.
OTLK Yearly Net Income VS EBIT VS OCF VS FCFOTLK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

OTLK's Return On Assets of 110.72% is amongst the best of the industry. OTLK outperforms 99.64% of its industry peers.
Industry RankSector Rank
ROA 110.72%
ROE N/A
ROIC N/A
ROA(3y)-215.73%
ROA(5y)-221.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OTLK Yearly ROA, ROE, ROICOTLK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K -1K

1.3 Margins

OTLK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OTLK Yearly Profit, Operating, Gross MarginsOTLK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

More info and screens

0

2. Health

2.1 Basic Checks

There is no outstanding debt for OTLK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
OTLK Yearly Shares OutstandingOTLK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
OTLK Yearly Total Debt VS Total AssetsOTLK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -54.76, we must say that OTLK is in the distress zone and has some risk of bankruptcy.
OTLK has a worse Altman-Z score (-54.76) than 94.11% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -54.76
ROIC/WACCN/A
WACCN/A
OTLK Yearly LT Debt VS Equity VS FCFOTLK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

2.3 Liquidity

A Current Ratio of 0.72 indicates that OTLK may have some problems paying its short term obligations.
The Current ratio of OTLK (0.72) is worse than 91.07% of its industry peers.
A Quick Ratio of 0.57 indicates that OTLK may have some problems paying its short term obligations.
OTLK has a Quick ratio of 0.57. This is amonst the worse of the industry: OTLK underperforms 92.14% of its industry peers.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.57
OTLK Yearly Current Assets VS Current LiabilitesOTLK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 105.05% over the past year.
EPS 1Y (TTM)105.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

OTLK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.60% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.67%
EPS Next 2Y26.71%
EPS Next 3Y21.1%
EPS Next 5Y19.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OTLK Yearly Revenue VS EstimatesOTLK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
OTLK Yearly EPS VS EstimatesOTLK Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200 -300

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 7.36 indicates a rather cheap valuation of OTLK.
OTLK's Price/Earnings ratio is rather cheap when compared to the industry. OTLK is cheaper than 98.04% of the companies in the same industry.
OTLK's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.25.
The Forward Price/Earnings Ratio is negative for OTLK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 7.36
Fwd PE N/A
OTLK Price Earnings VS Forward Price EarningsOTLK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OTLK Per share dataOTLK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
OTLK's earnings are expected to grow with 21.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.1
PEG (5Y)N/A
EPS Next 2Y26.71%
EPS Next 3Y21.1%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OTLK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OUTLOOK THERAPEUTICS INC

NASDAQ:OTLK (5/30/2025, 8:24:47 PM)

After market: 1.76 -0.08 (-4.35%)

1.84

+0.04 (+2.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-12 2025-08-12/bmo
Inst Owners16.1%
Inst Owner Change49.86%
Ins Owners0.24%
Ins Owner Change0%
Market Cap77.63M
Analysts83.33
Price Target10.71 (482.07%)
Short Float %17.27%
Short Ratio10.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)112.75%
Min EPS beat(2)34.42%
Max EPS beat(2)191.08%
EPS beat(4)4
Avg EPS beat(4)108.33%
Min EPS beat(4)18.46%
Max EPS beat(4)191.08%
EPS beat(8)6
Avg EPS beat(8)42.52%
EPS beat(12)8
Avg EPS beat(12)28.88%
EPS beat(16)9
Avg EPS beat(16)14.74%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-26.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 7.36
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.25
EY13.59%
EPS(NY)-1.89
Fwd EYN/A
FCF(TTM)-1.52
FCFYN/A
OCF(TTM)-1.52
OCFYN/A
SpS0
BVpS-0.77
TBVpS-0.77
PEG (NY)1.1
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 110.72%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-215.73%
ROA(5y)-221.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.72
Quick Ratio 0.57
Altman-Z -54.76
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)105.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.19%
EPS Next Y6.67%
EPS Next 2Y26.71%
EPS Next 3Y21.1%
EPS Next 5Y19.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-27.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-17.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.5%
OCF growth 3YN/A
OCF growth 5YN/A